Galactoside Inhibitor Design for Galectin-3 Binding and Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current galectin inhibitors, such as saccharides and synthetic compounds, face challenges due to hydrophilicity, poor absorption, and susceptibility to acidic hydrolysis, limiting their effectiveness as pharmaceutical agents for treating inflammation, fibrosis, cancer, and other diseases.
Innovation Solution
Development of novel α-D-galactopyranose compounds with specific structural modifications, such as alkyl substituents on the galactoside 2-OH, which exhibit high affinity for galectin-3 and improved pharmacokinetic properties for oral administration, including low clearance and high bioavailability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If natural saccharides are used as galectin inhibitors, then they can bind to galectins, but they are susceptible to acidic hydrolysis and have poor absorption
Solution Approach 1:
The patent modifies the chemical structure of natural saccharides by replacing the glycosidic oxygen with a carbon atom (C-glycoside) or other non-hydrolyzable linkages. This structural parameter change eliminates the susceptibility to acidic hydrolysis while preserving the galactose moiety that binds to galectins, thus maintaining reliability while improving stability.
Solution Approach 2:
The invention creates composite structures by combining the galactose binding unit with various stabilizing moieties and hydrophobic groups. These composite molecules integrate the functional saccharide portion with protective structural elements that prevent degradation and enhance pharmacokinetic properties, resolving the contradiction between binding ability and stability.
2Reliability
If natural saccharides are used as galectin inhibitors, then they can bind to galectins, but they have poor absorption and are not suitable for oral administration
Solution Approach 1:
The patent changes key physicochemical parameters of the saccharide molecules by introducing hydrophobic substituents, optimizing molecular weight, and modifying polarity. These parameter changes improve membrane permeability and oral absorption while the galactose core is preserved to maintain galectin binding ability.
Solution Approach 2:
The invention introduces intermediary hydrophobic groups and cell-permeable moieties that act as mediators to facilitate the transport of the hydrophilic galactose binding unit across biological membranes. These intermediary structures enable oral absorption without compromising the saccharide's ability to bind galectins.
3Ease of manufacture
If synthetic galectin inhibitors are developed, then absorption may be improved, but they may lose the specificity and affinity of natural saccharides
Solution Approach 1:
The patent applies local quality by preserving the critical galactose binding site (the local structure that interacts with galectin) while modifying distant parts of the molecule for improved pharmacokinetics. The galactose moiety and its key hydroxyl groups are maintained to ensure high binding affinity, while peripheral substituents are optimized for absorption and stability.
Solution Approach 2:
The invention segments the inhibitor molecule into distinct functional domains: a galactose binding domain that ensures specificity and affinity, and a pharmacokinetic optimization domain that improves absorption and stability. This segmentation allows independent optimization of each function without compromising the other.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds demonstrate enhanced galectin-3 affinity and improved drug-like properties, potentially offering effective treatment options for inflammation, fibrosis, cancer, and other diseases with reduced side effects.
Implementation Method 1
Galectins are proteins with a characteristic carbohydrate recognition domain (CRD)... a β-galactose binding site
Data Source
AI summary
A compound of the general formula (1). The compound of formula (1) is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Also, a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.